ArticleFrontiers in oncology2026
Bridging practice and precision: a quantitative HER2 protein assay ready for clinical use in guiding trastuzumab deruxtecan therapy.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Current daily usage of Trastuzumab Deruxtecan (T-DXd) is guided by immunohistochemistry (IHC)-based HER2 assessment, with known inconsistency and inaccuracy to differentiating IHC 0 from 1 +. In this study, a quantitative HER2 assay based on the Quantitative Dot Blot (QDB) method was explored to fill this unmet need. Methods: Consecutive resection specimens of HER2 IHC 0 and 1+ from invasive breast cancer patients were assigned to training (n=106) and validation cohorts ( Results: QDB was demonstrated to be more consistent than IHC with an inter-rater Intraclass Correlation Coefficient (ICC) of 0.877 (95%CI: 0.840-0.908) vs. 0.513 (95%CI: 0.433-0.601). Receiver Operating Characteristic (ROC) analysis was performed benchmarked with unanimous agreement of 18 pathologists in the training cohort to achieve an Area Under the Curve (AUC) of 0.9477 (p<0.005). A cutoff of 0.2746 nmole/g was also identified with its imprecision interval to stratify specimens into 0 (<C Conclusion: Our results supports the QDB HER2 assay as an alternative option to guide T-DXd daily usage by distinguish Her2-low from Her2 0 while setting the stage for outcome-based patient stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.